In the past decade, changes have occurred in the spectrum of multiple sclerosis courses.
The natural history of multiple sclerosis appears milder from the first sign of demyelinating …

Background Multiple sclerosis (MS) is an autoimmune, demyelinating disease of the central
nervous system. The treatment of MS has always been a focus of neurological research. To …

Objective To determine the effectiveness of high-efficacy disease-modifying therapies
(heDMTs) vs medium-efficacy disease-modifying therapies (meDMT) as the first treatment …

Objective During the natural course of multiple sclerosis (MS), the brain is exposed to aging
as well as disease effects. Brain aging can be modeled statistically; the so‐called “brain …

Oral siponimod (Mayzent®), a next-generation, selective sphingosine 1-phosphate receptor
(S1PR) 1 and 5 modulator, is approved in several countries for the treatment of secondary …

Interferon beta (IFNβ) was the first disease-modifying therapy available to treat multiple
sclerosis (MS), providing patients with a treatment that resulted in reduced relapse rates and …

Multiple sclerosis (MS) is the most common acquired demyelinating disorder of the central
nervous system (CNS). Diagnosing MS can be very challenging owing to its variable clinical …

Aim: To compare the efficacy of ofatumumab to other disease-modifying therapies (DMTs)
for relapsing multiple sclerosis (RMS). Materials & methods: A network meta-analysis was …

Background Family planning is an important consideration for women with multiple sclerosis
(MS), who are often diagnosed during their reproductive years. Currently, limited data are …

Randomized controlled clinical trials and real-world observational studies provide
complementary information but with different validity. Some clinical questions (disease …